SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Veris Residential completed a merger transaction on May 27, 2026, in which the Company merged with Merger Sub I and its partnership merged with Merger Sub II, resulting in a change of control. All outstanding shares and units were converted into cash consideration of $19.00 per share, and the Company became a subsidiary of Parent while ceasing to exist as an independent entity.
View raw filing on EDGAR →The NYSE suspended trading and delisted Veris Residential's shares on May 27, 2026, in connection with the merger consummation. The NYSE filed Form 25 to report the delisting and effect deregistration under Section 12(b) of the Exchange Act, and the Company intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →Item 3.03 discloses a material modification to security holder rights in connection with the merger transaction and related corporate restructuring, incorporating references to the acquisition completion, delisting, change of control, and amendments to articles and bylaws.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder meeting results held on May 21, 2026. The filing reports voting outcomes for three proposals: election of five directors (Kapila K. Anand, Paul Herendeen, Michael Harrington, Lawrence Kurzius, and Kirk McDonald), ratification of Ernst & Young LLP as independent auditor, and non-binding approval of named executive officer compensation. All proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →Redwood Trust completed a registered public offering of $125 million in senior notes on May 27, 2026, with net proceeds of approximately $120.41 million intended for general corporate purposes, funding operating businesses, and strategic acquisitions.
View raw filing on EDGAR →The filing discloses a dividend announcement under Item 2.02 (Results of Operations and Financial Condition), but the prose does not describe earnings results, financial performance, or operational metrics. A dividend announcement is material to investors as it signals capital allocation and financial health, but it does not fit the earnings_release category (which typically covers quarterly/annual financial results). This is best classified as other_material since it is a material capital allocation event that falls outside the more specific taxonomy categories.
View raw filing on EDGAR →Primis Financial Corp. held its 2026 Annual Meeting of Stockholders on May 21, 2026, with shareholders voting on three proposals: election of ten directors, ratification of Crowe, LLP as independent auditors, and an advisory vote on named executive officer compensation. All three proposals passed with detailed vote tallies reported for each nominee and proposal.
View raw filing on EDGAR →Primis Financial Corp. appointed two new directors, Scott R. Gamble and J. Brock Saunders, to the Board of Primis Financial Corp. and its subsidiary bank, effective May 21, 2026, with specified committee assignments. The appointments follow the non-re-election of two departing directors and reflect changes to board composition.
View raw filing on EDGAR →The filing discloses Salesforce's quarterly financial results for the fiscal quarter ended April 30, 2026, via a press release attached as Exhibit 99.1. Item 2.02 is the standard disclosure vehicle for earnings releases, and the prose explicitly states the Company "issued a press release announcing its results for the fiscal quarter." Quarterly earnings are material to investors' assessment of the registrant's financial performance and condition.
View raw filing on EDGAR →BridgeBio announced FDA acceptance and priority review of an NDA for BBP-418, a significant regulatory milestone for a drug candidate. While this is a material event affecting investor assessment of the company's pipeline progress and regulatory prospects, it does not fit neatly into the more specific event categories (it is neither an earnings release, executive change, M&A activity, nor a negative event like impairment or litigation). This is best classified as other_material.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Immunocore's 2026 Annual General Meeting held on May 27, 2026. The filing presents the voting outcomes for ten resolutions, including director re-appointments, executive compensation approval, auditor ratification, and financial statement adoption—all standard AGM matters. Item 5.07 explicitly requires disclosure of shareholder meeting results, and the detailed vote tallies (for, against, abstain) for each resolution are the core content of this 8-K section.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of BlackRock Private Credit Fund's 2026 Annual Meeting of Shareholders held on May 27, 2026, where shareholders voted to elect Eric J. Draut as a Class I Trustee to the Board. The filing provides the specific voting tallies (54,507,236 votes for, 637,132 withheld) and confirms the proposal was approved. Board elections are material governance events affecting investor oversight and fund management.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from BlackRock Direct Lending Corp.'s 2026 Annual Meeting of Shareholders held on May 27, 2026. The filing explicitly presents the election of four directors (Eric J. Draut, Karen L. Leets, Maureen K. Usifer, and Philip Tseng) with detailed voting tallies showing unanimous approval (29,076,852 votes for each, zero withheld). Director elections are material governance events that affect the composition of the board and are routinely disclosed via Item 5.07.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from BlackRock TCP Capital Corp.'s 2026 Annual Meeting of Stockholders held on May 27, 2026. The filing presents the election of six directors (Eric J. Draut, Karen L. Leets, Andrea L. Petro, Maureen K. Usifer, John R. Baron, and Philip Tseng) with detailed vote tallies showing "For," "Withheld," and "Broker Non-Votes" for each candidate. Board composition is material to investors' assessment of corporate governance and oversight.
View raw filing on EDGAR →comScore completed the sale of its box office measurement and Hollywood Software businesses to Flix Buyer Inc. (an Advaya Capital affiliate) for $70.0 million in cash on May 27, 2026. This constitutes a material disposition of business units. The company simultaneously used proceeds to repay and terminate its $40.1 million Credit Agreement, eliminating all debt obligations. This is a significant M&A transaction affecting the company's asset base and capital structure.
View raw filing on EDGAR →This is a straightforward earnings release disclosure under Item 2.02. The company issued a press release announcing financial results for its third fiscal quarter ended April 30, 2026, with the press release attached as Exhibit 99.1. Quarterly earnings releases are material events that affect investor assessment of the registrant's financial performance and condition.
View raw filing on EDGAR →The Trust entered into a Purchase and Sale Agreement on May 26, 2026, to sell 100% of its ownership interests in Westwood Plaza shopping center for $28.8 million to an affiliate of Regency Centers Corporation. This is a material disposition of a real estate asset, which constitutes a material acquisition/disposition event under Item 1.01. The transaction is material to investors as it represents a significant asset sale for a REIT.
View raw filing on EDGAR →PBF Energy announced a $500 million private offering of senior unsecured notes due 2034 by its subsidiaries. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the dilutive_issuance category (which focuses on equity securities) or other specific event types. This is a material financing event disclosed under Item 8.01 that warrants classification as other_material.
View raw filing on EDGAR →Apollo Asset Backed Credit Co LLC completed unregistered sales of equity securities totaling approximately $52.6 million across Series I and Series II share classes to third-party investors, exempt under Section 4(a)(2) and Regulations D and S.
View raw filing on EDGAR →The company determined Net Asset Value per share across multiple share classes as of April 30, 2026, and declared distributions payable to shareholders, material to investors assessing share pricing and shareholder returns.
View raw filing on EDGAR →Rani entered into a securities purchase agreement on May 26, 2026, to issue 12,476,637 shares of Class A common stock and 6,214,953 pre-funded warrants for approximately $20.0 million in gross proceeds. This is a classic dilutive equity issuance to institutional investors, disclosed under Item 8.01 (Other Events). The transaction includes lock-up agreements and a 90-day lock-up on further issuances, typical of PIPE-like offerings that materially dilute existing shareholders.
View raw filing on EDGAR →Bain Capital Private Credit entered into a material definitive agreement to increase aggregate commitments under its Revolving Credit Facility from $200 million to $250 million through an accordion feature, expanding the company's committed credit capacity by $50 million.
View raw filing on EDGAR →Lumen Technologies held its Annual Meeting of shareholders on May 20, 2026, with voting results disclosed across seven proposals including election of nine directors, ratification of KPMG LLP as independent auditor, amendments to Articles of Incorporation, approval of the Amended and Restated 2024 Equity Incentive Plan, advisory vote on named executive officer compensation, and a shareholder proposal regarding shareholder rights plans.
View raw filing on EDGAR →This Item 7.01 disclosure centers on an Investor Day presentation where TTM Technologies reiterates fiscal 2026 guidance ($4.0B revenue, 13-15% non-GAAP operating margin, 16-18% Adjusted EBITDA margin) and announces material refinancing activity: a $400M repriced Term Loan (reducing borrowing costs by 50 bps) and a new $1B Revolving Credit facility to replace existing ABL facilities, both expected to close in June 2026. While the guidance update resembles forward-looking statements and the refinancing involves debt restructuring, the disclosure does not fit cleanly into earnings_release (no actual results), ma_activity (no acquisition/disposition), or covenant_breach (no violation). The refinancing is material to investors assessing capital structure and financial flexibility, but the Item 7.01 format and forward-looking nature (subject to closing conditions) place it outside the more specific event categories.
View raw filing on EDGAR →The disclosure announces that the German Federal Cartel Office granted final merger control clearance for the Klöckner Acquisition on May 27, 2026, satisfying the last regulatory condition required for closing. The filing explicitly states that "all conditions set forth in the offer document have been satisfied and the Company and BidCo expect to consummate the Klöckner Acquisition on June 3, 2026." This is a material acquisition event that would significantly affect a reasonable investor's assessment of Worthington Steel's future operations, financial condition, and strategic direction.
View raw filing on EDGAR →The filing discloses the sale of MarkForged, Inc. to Stratasys, which constitutes a material disposition or divestiture of a significant asset. Although disclosed under Item 8.01 (Other Events) rather than the typical Item 1.02 (Unregistered Sales of Equity Securities) or Item 2.01 (Completion of Acquisition or Disposition of Assets), the substance is clearly a material M&A transaction—the sale of a subsidiary. This would materially affect investor assessment of Nano Dimension's asset base and strategic direction.
View raw filing on EDGAR →Monro, Inc. disclosed financial results for the fourth quarter and fiscal year ended March 28, 2026 via press release furnished as Exhibit 99.1.
View raw filing on EDGAR →The company announced initiation of a strategic alternatives review on May 27, 2026, signaling potential material corporate action such as a merger, sale, or restructuring, though the specific nature and outcome of alternatives being considered were not disclosed.
View raw filing on EDGAR →American Tower completed a registered public offering of €750 million in senior unsecured notes due 2033, generating approximately $866.7 million in net proceeds. This significant debt issuance affects the company's capital structure and liquidity.
View raw filing on EDGAR →Cheniere Partners entered into a Purchase Agreement on May 26, 2026 to issue $1.75 billion in aggregate principal amount of senior notes ($1 billion due 2036 and $750 million due 2056), with proceeds intended to fund a $1.5 billion redemption of existing 5.00% Senior Secured Notes due 2027. This material capital-raising and refinancing activity affects the company's financial structure and long-term obligations.
View raw filing on EDGAR →Cheniere Partners entered into a Purchase Agreement on May 26, 2026, to issue $1.75 billion in aggregate principal amount of senior notes ($1 billion due 2036 and $750 million due 2056), with proceeds intended to fund a $1.5 billion redemption of existing 5.00% Senior Secured Notes due 2027. This material debt refinancing represents a significant capital structure transaction.
View raw filing on EDGAR →Jaguar Health regained compliance with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)) as of May 26, 2026, but remains subject to a mandatory one-year Panel Monitor period with a critical condition: failure to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days would result in immediate delisting without the standard 180-day grace period.
View raw filing on EDGAR →Warner Bros. Discovery obtained requisite consents for amendments to indentures related to the pending Paramount Skydance acquisition. The supplemental indentures modify the timing and terms of required exchange transactions contingent on the Acquisition's consummation or termination, representing a material step in the merger transaction.
View raw filing on EDGAR →Vista Credit Strategic Lending Corp. completed an unregistered sale of approximately $5.0 million in Class I and Class S common stock pursuant to subscription agreements, relying on Section 4(a)(2) and Regulations D and S exemptions.
View raw filing on EDGAR →The Company disclosed its NAV per share as of April 30, 2026 ($19.21), total investments of $1.9 billion, and a debt-to-equity ratio of 0.82x, providing investors with key financial metrics and portfolio composition data.
View raw filing on EDGAR →The filing discloses an unregistered sale of equity securities (common stock) pursuant to Item 3.02, with an aggregate offering price of $29.7 million. The shares are being issued under subscription agreements to existing investors via capital calls, exempt from Securities Act registration under Section 4(a)(2) and Regulation D. This is a classic dilutive issuance of unregistered equity that would materially affect investor assessment of share ownership and capitalization.
View raw filing on EDGAR →This disclosure describes the entry into multiple definitive material agreements on May 27, 2026, centered on a $1.268 billion asset-backed securitization transaction. NMAC transferred retail motor-vehicle installment sales contracts (Receivables) to NARC II, which then transferred them to the Issuing Entity, resulting in the issuance of $1.268 billion in asset-backed notes sold to major underwriters. This constitutes a material acquisition and disposition of assets with significant financial impact, fitting the ma_activity classification under Item 1.01.
View raw filing on EDGAR →The filing discloses issuance of $90 million in First Mortgage Bonds ($35M at 5.91% due 2036 and $55M at 6.65% due 2056) pursuant to Item 2.03. While this creates a direct financial obligation, it is a routine debt issuance by a utility company rather than a covenant breach, going-concern issue, or other acute financial stress signal. The bonds were issued to institutional investors in reliance on Section 4(a)(2) exemption and are secured by the company's mortgage. This is material to investors but does not fit the more specific event categories (covenant_breach, going_concern, bankruptcy_filing, etc.) and is best classified as other_material.
View raw filing on EDGAR →EQT Infrastructure Company LLC disclosed unregistered sales of equity securities totaling approximately $89.8 million in Investor Shares (Class A-I, A-S, M-I, and M-S) as of May 1, 2026, plus an additional issuance of approximately 239,536 Class E Shares valued at ~$6.6 million to EQT Holdings AB on May 26, 2026. Both offerings were exempt from registration under Section 4(a)(2) and Regulations D and S. The filing explicitly states this is part of a continuous private offering that has raised approximately $539.6 million since inception on February 1, 2026, representing a material capital raise through unregistered equity issuances.
View raw filing on EDGAR →EQT Private Equity Company LLC disclosed unregistered sales of equity securities totaling approximately $28.9 million in Investor Shares (Classes A-I, A-J1, A-J2, A-S) and $58.1 million in Class E Shares to EQT Holdings AB, all exempt from registration under Section 4(a)(2) and Regulation D/S. This is a classic dilutive issuance disclosure under Item 3.02, representing continuous private offerings that have cumulatively raised approximately $746.2 million since inception in July 2025.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Cytokinetics' Annual Meeting of Stockholders held on May 27, 2026. The filing reports voting outcomes for four proposals: election of three Class I directors (Kaye, Wierenga, Wysenski), approval of an amendment to the 2015 Employee Stock Purchase Plan, ratification of Ernst & Young LLP as independent auditor, and an advisory vote on executive compensation. All proposals passed with substantial majorities, making this a material disclosure of governance and shareholder approval outcomes.
View raw filing on EDGAR →Geron Corp held its 2026 Annual Meeting of Stockholders on May 20, 2026, with shareholders voting on four proposals: election of three Class III directors, approval of an amendment to the 2018 Equity Incentive Plan increasing the share reserve by 4.5 million shares, an advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four matters: election of eight directors, ratification of PricewaterhouseCoopers LLP as independent auditor, amendment to the Employee Stock Purchase Plan authorizing 700,000 additional shares, and an advisory vote on executive compensation. All four proposals passed by majority vote. Shareholder vote results are material to investors as they confirm governance and compensation decisions.
View raw filing on EDGAR →Stepstone Private Credit Fund LLC completed an unregistered sale of 5,680,855 LLC interests for $148.1 million pursuant to subscription agreements, relying on Section 4(a)(2), Regulation D, and/or Regulation S exemptions. This private placement raises material capital while diluting existing investors.
View raw filing on EDGAR →Q32 Bio entered into a securities purchase agreement to sell 6,725,000 shares of common stock and 150,000 pre-funded warrants to accredited investors for approximately $55 million in gross proceeds under a PIPE (private investment in public equity) transaction relying on Section 4(a)(2) exemption. The company plans to file a Registration Statement for resale of the securities.
View raw filing on EDGAR →The Company retracted a press release announcing entry into a credit facility for its credit card program and clarified that no such facility has been entered into. This is a material correction of a prior public statement that could have affected investor expectations about the Company's financing and operational capacity. While the retraction itself is a corrective disclosure rather than a new material event, the fact that a material misstatement was publicly issued and then retracted warrants disclosure as a material event affecting the total mix of information available to investors.
View raw filing on EDGAR →Aptevo entered into a material collaboration agreement with Niowave on May 25, 2026, involving joint development of a therapeutic product combining Aptevo's proprietary molecules (APVO455) and Niowave's radioisotopes (Actinium-225), coupled with a concurrent stock purchase agreement under which Niowave acquired 98,522 shares and 53,201 warrants for $500,000, with options for up to ~97,373 additional shares.
View raw filing on EDGAR →The Fund reported NAV per share of $22.39 as of April 30, 2026, aggregate NAV of $4.4 billion, portfolio fair value of $7.0 billion, and debt-to-equity leverage of 0.63x, while updating the status of ongoing public and private share offerings totaling approximately $4.8 billion in consideration to date.
View raw filing on EDGAR →The filing discloses issuance of $1.375 billion in Series 2026-A Senior Secured SAC Bonds by Appalachian Power Recovery Funding LLC on May 27, 2026, pursuant to an Indenture and Series Supplement. While this is a material debt issuance that would affect investor assessment of the registrant's capital structure and financial obligations, it does not fit cleanly into the M&A activity category (which focuses on acquisitions, dispositions, mergers, or changes of control) and is disclosed under Item 8.01 (Other Events) rather than Item 1.01 or 2.01. The event is material but lacks a more specific taxonomy match.
View raw filing on EDGAR →Oncor entered into a Junior Subordinated Indenture and issued €850 million (approximately US$974.3 million) of junior subordinated notes due 2056. The proceeds were used for general corporate purposes and commercial paper repayment, constituting a material financing event affecting the company's capital structure.
View raw filing on EDGAR →